Core Viewpoint - The company, Reap Bio (300119.SZ), has received a new veterinary drug registration certificate from the Ministry of Agriculture and Rural Affairs for a multi-strain inactivated vaccine targeting avian diseases, marking a significant advancement in the poultry vaccine market in China [1] Group 1: Product Approval - The company and its subsidiaries have obtained the new veterinary drug registration certificate for a vaccine that includes strains for Newcastle disease, infectious bronchitis, avian influenza (H9 subtype), and infectious bursal disease [1] - This product approval fills a market gap for QX-type infectious bronchitis virus multi-strain vaccines in China [1] Group 2: Strategic Implications - The approval reflects the company's forward-looking layout and innovative capabilities in the poultry vaccine sector [1] - The new vaccine enhances the company's product line in poultry vaccines, which is expected to further solidify its leading position in the industry [1] - The introduction of this product is anticipated to provide a new growth point for the company's performance [1]

Core Viewpoint - Reap Bio (300119.SZ) has received a new veterinary drug registration certificate from the Ministry of Agriculture and Rural Affairs for a multi-strain inactivated vaccine targeting avian diseases, marking a significant advancement in the poultry vaccine market in China [1] Group 1: Product Approval - The new veterinary drug is a four-in-one inactivated vaccine for Newcastle disease, infectious bronchitis, avian influenza (H9 subtype), and infectious bursal disease [1] - The approval fills a market gap for QX-type infectious bronchitis virus multi-strain vaccines in China [1] Group 2: Company Positioning - The product reflects the company's forward-looking layout and innovative capabilities in the poultry vaccine sector [1] - The new vaccine enhances the company's poultry vaccine product line, helping to solidify its leading position in the industry [1] - The introduction of this vaccine is expected to provide a new growth point for the company's performance [1]

根据《兽药管理条例》和《兽药注册办法》的规定，瑞普生物股份有限公司 （以下简称"公司""瑞普生物"）及下属分子公司天津瑞普生物技术股份有限 公司空港经济区分公司、瑞普（保定）生物药业有限公司、广州市华南农大生物 药品有限公司近日获得由农业农村部核发的《新兽药注册证书》，详情如下： | 新兽药名称 | | | 研制单位 | 类别 | 新兽药注册证号 | | --- | --- | --- | --- | --- | --- | | 鸡新城疫、传染性支气管 | | | | | | | | | | 瑞普生物股份有限公司、天津 | | | | 亚型）、 | 炎、禽流感（H9 | | 瑞普生物技术股份有限公司空 | | | | 传染性法氏囊病四联灭活 | | | | | （2025）新兽药证字 | | | | | 港经济区分公司、瑞普（保定） | 三类 | | | 疫 苗 株 | （ La | Sota | | | 111 号 | | | | | 生物药业有限公司、广州市华 | | | | 株 +RPVA0406 +TJ-4 | 株 | | | | | | | | | 南农大生物药品有限公司 | | | | +RPVA ...

Core Insights - The report maintains a positive outlook on the pig farming industry, recommending continued investment in pig farming despite recent price declines due to supply pressures [1][7][21] - The report highlights a significant drop in pig prices, with the average price for market pigs at 12.67 yuan/kg, down 3.65% week-on-week [7][32][33] - The report indicates ongoing losses in pig farming, with self-breeding and purchased pig farming yielding losses of 74.11 yuan/head and 236.57 yuan/head respectively [7][37] Industry Overview - The agricultural sector index has decreased by 1.97% week-on-week, while the Shanghai and Shenzhen 300 index increased by 1.07% [11] - Since January 2, 2025, the agricultural sector has seen a total increase of 16.95%, compared to a 15.63% increase in the Shanghai and Shenzhen 300 index [12][11] - The report notes that the pig farming sector is currently in a downward cycle, with supply pressures gradually being released [21] Pig Farming Data Tracking - The number of breeding sows has slightly decreased by 0.80% month-on-month in August, indicating a potential reduction in future supply [22][7] - The average weight of market pigs at the time of sale is reported at 128.55 kg [22][8] - The report emphasizes that the current breeding and purchasing sentiment is declining due to stricter environmental regulations and market conditions [17][21] Poultry Farming Data Tracking - The average price for white feathered chickens is reported at 6.90 yuan/kg, with a slight increase of 0.29% week-on-week [38][41] - The report notes that the poultry industry is facing uncertainties due to ongoing outbreaks of avian influenza in overseas markets [38][39] Animal Health Data Tracking - The demand for animal health products is expected to rebound, with significant growth in vaccine approvals and product launches [46] - The report highlights that the industry is seeing a recovery in sales, with some vaccines showing substantial year-on-year growth [46] Seed Industry Data Tracking - The average prices for wheat, soybean meal, and corn have shown slight increases, indicating a potential upward trend in agricultural input costs [50] - The report emphasizes the importance of food security and the need for advancements in agricultural biotechnology [50] Pet Industry Data Tracking - Pet food exports have decreased by 15.5% year-on-year, with a total export value of 834 million yuan in August 2025 [55][56] - Domestic sales of pet food continue to grow, with significant increases reported on e-commerce platforms [57] - The report suggests that companies with strong domestic sales and innovative product offerings are likely to gain market share [59]

Core Viewpoint - The company announced a change in the use of part of the funds raised from a specific stock issuance in 2021, redirecting them towards the construction of a "Biomanufacturing Industrialization Project" [1] Group 1 - The company held its 27th (temporary) meeting of the fifth board of directors on September 28, 2025, to review the proposal [1] - The proposal to change the use of funds requires approval from the company's shareholders' meeting [1]

Core Insights - The animal health sector experienced a slight increase of 0.46% on September 29, with Shenlian Biological leading the gains [1] - The Shanghai Composite Index closed at 3862.53, up 0.9%, while the Shenzhen Component Index closed at 13479.43, up 2.05% [1] Stock Performance - Shenlian Biological (688098) closed at 10.59, up 1.92% with a trading volume of 68,700 shares and a turnover of 72.32 million yuan [1] - Other notable performers included: - Biological Shares (600201) at 9.48, up 1.50% with a turnover of 503 million yuan [1] - Pulaike (603566) at 13.78, up 1.03% with a turnover of 54.30 million yuan [1] - Zhongmu Shares (600195) at 7.12, up 0.85% with a turnover of 49.02 million yuan [1] Capital Flow - The animal health sector saw a net outflow of 7.69 million yuan from institutional investors, while retail investors contributed a net inflow of 8.08 million yuan [2] - The detailed capital flow for key stocks includes: - Shenlian Biological: net outflow of 5.50 million yuan from retail investors [3] - Biological Shares: net outflow of 7.67 million yuan from retail investors [3] - Pulaike: net outflow of 4.08 million yuan from retail investors [3]

Core Viewpoint - The company plans to allocate a total of 160 million yuan from the "South China Biological Large-Scale Suspension Culture Workshop Construction Project" and 115 million yuan from the remaining funds of the "Zhong'an Biological Expansion and Renovation Project" to the "Biomanufacturing Industrialization Engineering Construction Project" [1] Group 1 - The total investment for the new project is 679 million yuan, with 296 million yuan sourced from raised funds [1] - The implementation entities for the new investment project are the company and its wholly-owned subsidiary, Tianjin Ruishi Biotechnology Co., Ltd [1] - The project will be located in the Tianjin Port Free Trade Zone, Lingang area [1] Group 2 - The raised funds include 20.8231 million yuan from interest income and financial management returns, which will be deducted from the total amount [1] - The remaining investment will be financed through the company's own funds or self-raised funds [1]

关于瑞普生物股份有限公司 中国银河证券股份有限公司 变更部分募集资金用途 的核查意见 瑞普生物股份有限公司（以下简称"公司""瑞普生物"）于 2025 年 9 月 28 日 召开第五届董事会第二十七次（临时）会议，审议通过了《关于变更部分募集资金用 途的议案》，同意公司变更 2021 年向特定对象发行股票部分募集资金投资项目用途， 用于建设"生物制造产业化工程建设项目"，该议案已经公司第五届监事会第二十三 次（临时）会议审议通过，尚需提交公司股东大会审议。 中国银河证券股份有限公司（以下简称"银河证券"或"保荐人"）作为瑞普生 物 2021 年度向特定对象发行股票的保荐人，根据《证券发行上市保荐业务管理办法 （2025 修正）》《深圳证券交易所创业板股票上市规则（2025 年修订）》《深圳证 券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作（2025 年修订）》 《上市公司募集资金监管规则》等相关规定，对公司变更部分募集资金用途事项进行 了审慎核查，具体核查情况和核查意见如下： 一、改变募集资金投资项目的概述 （一）募集资金基本情况 经中国证券监督管理委员会于 2021 年 9 月 10 日下 ...

证券代码：300119 证券简称：瑞普生物 公告编号：2025-076 瑞普生物股份有限公司（以下简称"公司""瑞普生物"）于 2025 年 9 月 28 日召开第五届董事会第二十七次（临时）会议，审议通过了《关于变更部分 募集资金用途的议案》，同意公司变更 2021 年向特定对象发行股票部分募集资 金投资项目用途，用于建设"生物制造产业化工程建设项目"，该议案尚需提交 公司股东大会审议。 现将具体情况公告如下： 一、改变募集资金投资项目的概述 （一）募集资金基本情况 经中国证券监督管理委员会于 2021 年 9 月 10 日下发的《关于同意天津瑞普 生物技术股份有限公司向特定对象发行股票注册的批复》（证监许可〔2021〕2974 号），同意公司向特定对象发行人民币普通股（A 股）63,984,674 股，发行价格 为人民币 20.88 元/股，募集资金总额为人民币 1,335,999,993.12 元，扣除各项发 行 费 用 （ 不 含 税 ） 人 民 币 13,979,522.73 元 后 ， 募 集 资 金 净 额 为 人 民 币 1,322,020,470.39 元。 上述募集资金于 2021 年 1 ...

证券代码：300119 证券简称：瑞普生物 公告编号：2025-077 瑞普生物股份有限公司 关于召开 2025 年第五次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、本次股东大会召开的基本情况 1、股东大会届次：2025年第五次临时股东大会 2、会议召集人：经公司第五届董事会第二十七次（临时）会议审议通过， 公司董事会决定召开2025年第五次临时股东大会。 3、会议召开的合法、合规性：本次股东大会的召集程序符合有关法律、行 政法规、部门规章、规范性文件和《公司章程》的规定。 4、会议召开时间： 5、会议的召开方式：本次股东大会采取现场投票与网络投票相结合的方式。 现场会议召开时间：2025 年 10 月 15 日（星期三）14:30 （1）现场投票：包括本人出席及通过填写授权委托书授权他人出席。 网络投票时间为： （2）网络投票：公司将通过深圳证券交易所交易系统和互联网投票系统向 股东提供网络形式的投票平台，公司股东应在本通知列明的有关时限内通过深圳 证券交易所的交易系统或互联网投票系统进行网络投票。 通过深圳证券交易所交易系统进行 ...